Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

March
13
2019

Sensus Healthcare to Present at the 31st Annual ROTH Conference

BOCA RATON, Fla., March 13, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of…

March
12
2019

Sensus Healthcare Launches SRT University, an Online Portal to Support Physicians

New Online Portal System to Offer Training and Education Related to SRT Devices and Technology BOCA RATON, Fla., March 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective,…

March
05
2019

Technology Networks: Superficial Radio Therapy: A non-surgical Treatment for Non-melanoma Skin Cancers

Skin cancer can be broadly split in to two types: melanoma and non-melanoma. The most common non-melanomas include basal cell carcinoma and squamous cell carcinoma, for which the main treatment is surgery. However, other non-surgical…

March
04
2019

Thrive Global – The Future of Healthcare: “Using painless, low-dose radiation that only goes skin deep to destroy cancer cells — without damaging health tissue” with Joseph C. Sardano, CEO of Sensus Healthcare, Inc.

As a part of my series about “The Future of Healthcare” I had the pleasure of interviewing Joseph C. Sardano, Chief Executive Officer, Sensus Healthcare Inc. A recognized leader in the healthcare industry, Joe Sardano…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy